The earnings call reflects a positive sentiment with strong performance in the innovative portfolio and substantial progress in transformation programs. Although there are challenges in the generics segment and potential tariff impacts, the company's growth in innovative products and financial improvements outweigh these concerns.

Company Guidance -

Q3 2025

During the Q2 2025 earnings call for Teva Pharmaceutical Industries, the company provided several key financial metrics and guidance updates. Revenue for the quarter rose to $4.2 billion, marking the 10th consecutive quarter of growth, driven by the strong performance of innovative products like AUSTEDO, UZEDY, and AJOVY. AUSTEDO's revenue reached just under $500 million, reflecting a 19% increase, while UZEDY and AJOVY saw impressive growth of 120% and 31%, respectively. The company reported an adjusted EBITDA increase of 7% and a non-GAAP EPS growth of 10%. Teva continues to focus on its pivot to growth strategy, aiming for mid-single-digit average growth by 2027, and has reaffirmed its 2025 guidance, with expected revenue between $16.8 billion and $17.2 billion. The company also highlighted its commitment to achieving a 30% operating margin by 2027, driven by approximately $700 million in net savings from its ongoing transformation programs.

Innovative Product Growth

AUSTEDO, UZEDY, and AJOVY showed strong growth, with revenue increases of 19%, 120%, and 31% respectively. Overall, the innovative portfolio delivered a 27% increase in revenue.

10th Consecutive Quarter of Growth

Teva achieved its 10th consecutive quarter of growth with revenues up 1% to $4.2 billion, driven by innovative products.

Improved Financial Metrics

Adjusted EBITDA increased by 7% and non-GAAP EPS rose by 10%. The company reduced its net debt to EBITDA ratio to just over 3.

Biosimilars and Generics Pipeline

Teva plans to launch 15 complex generics and 8 biosimilars between now and 2027, with biosimilar sales expected to grow $400 million by 2027.

Transformation Program Progress

Teva is on track to achieve $700 million in net savings by 2027, with 20% of this achieved already.

Strong Pipeline Progress

Late-stage pipeline products are on track, with expected peak sales over $10 billion. The company also announced a strategic partnership with Fosun Pharma.

Teva Pharmaceutical (TEVA) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

TEVA Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 06, 2025	2025 (Q3)	0.70 / -	0.69	―	―	―
Jul 30, 2025	2025 (Q2)	0.62 / 0.66	0.61	8.20% (+0.05)
May 07, 2025	2025 (Q1)	0.46 / 0.52	0.48	8.33% (+0.04)
Jan 29, 2025	2024 (Q4)	0.71 / 0.71	1	-29.00% (-0.29)
Nov 06, 2024	2024 (Q3)	0.66 / 0.69	0.6	15.00% (+0.09)
Jul 31, 2024	2024 (Q2)	0.55 / 0.61	0.56	8.93% (+0.05)
May 08, 2024	2024 (Q1)	0.51 / 0.48	0.4	20.00% (+0.08)
Jan 31, 2024	2023 (Q4)	0.77 / 1.00	0.71	40.85% (+0.29)
Nov 08, 2023	2023 (Q3)	0.61 / 0.60	0.59	1.69% (+0.01)
Aug 02, 2023	2023 (Q2)	0.53 / 0.56	0.68	-17.65% (-0.12)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

TEVA Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jul 30, 2025	$16.54	$16.83	+1.75%
May 07, 2025	$16.12	$17.60	+9.18%
Jan 29, 2025	$21.53	$18.54	-13.89%
Nov 06, 2024	$18.77	$17.43	-7.14%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.